About Shenzhen Chipscreen Biosciences Company

The company was founded in March 2001 and is a pioneer in the field of innovative pharmaceuticals in China. Adhering to the concept of “originality, safety, efficiency, and China”, the company focuses on research and development of original innovative drugs in the five major fields of malignant tumors, metabolic diseases, autoimmune diseases, central nervous system diseases, and antivirals that pose a serious threat to human life and health, and is committed to providing patients with innovative mechanism drugs that are affordable, clinically needed, and have revolutionary curative effects. The company was the first company to participate in the Star and the first CNI Biomedicine Index company to go public. The company is an original innovative pharmaceutical enterprise that is driven by core technology and has built a globally competitive product line. The company's main products include sidabendamide, dipropine siglitazide, sioronil, CS23546, CS231295, CS32582, and other products under development. Corporate honors: the title of “Emerging Enterprise of the Year” at the 2019 The Guangdong-hk-macao Greater Bay Area-related Listed Companies Annual Meeting and Corporate Social Responsibility Summit, the title of “Leading Enterprise” in the 70th anniversary of the founding of New China in the pharmaceutical industry, and the title of “Leading Enterprise” among the top 20 leading biotechnology enterprises in Shenzhen in 2019.